M. Ashlock

发表

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Jinglan Zhou, P. Negulescu, P. Grootenhuis, 2009, Proceedings of the National Academy of Sciences.

Human artificial chromosomes generated by modification of a yeast artificial chromosome containing both human alpha satellite and single-copy DNA sequences.

X. Guan, M. Ashlock, P. Liu, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease.

E. Olson, M. Ashlock, Eric R Olson, 2011, Annual review of medicine.

Cystic fibrosis foundation: achieving the mission.

C. Penland, M. Ashlock, B. Marshall, 2009, Respiratory care.

An international randomized multicenter comparison of nasal potential difference techniques.

J. Clancy, F. Accurso, F. Vermeulen, 2010, Chest.

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

J. Clancy, S. Freedman, F. Accurso, 2010, The New England journal of medicine.

Isolation of human transcripts expressed in hamster cells from YACs by cDNA representational difference analysis.

X. Guan, M. Ashlock, J. Gu, 1999, Genome research.

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

P. Negulescu, P. Grootenhuis, F. van Goor, 2009, Proceedings of the National Academy of Sciences.

Humanizing the yeast telomerase template.

M. Ashlock, P. Liu, K. Henning, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Fluorescent chloride indicators to assess the efficacy of CFTR cDNA delivery.

A. Verkman, M. Ashlock, J. Biwersi, 1999, Human gene therapy.

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

P. Negulescu, P. Grootenhuis, J. Wine, 2011, Proceedings of the National Academy of Sciences.

Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR Function

R. Szczesniak, J. Clancy, S. Donaldson, 2013, PloS one.

CFTR intron 1 increases luciferase expression driven by CFTR 5'-flanking DNA in a yeast artificial chromosome.

M. Ashlock, P. Mogayzel, 2000, Genomics.

Positional cloning utilizing genomic DNA microarrays: the Niemann-Pick type C gene as a model system.

M. Bittner, P. Meltzer, Y. Chen, 2000, Molecular genetics and metabolism.

Secreted Histidyl-tRNA Synthetase Splice Variants Elaborate Major Epitopes for Autoantibodies in Inflammatory Myositis*

K. Chiang, M. Ashlock, Xiang-Lei Yang, 2014, The Journal of Biological Chemistry.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

J. Clancy, M. Ballmann, F. Accurso, 2011, Thorax.

Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

J. Clancy, F. van Goor, F. Accurso, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Transient gene expression from yeast artificial chromosome DNA in mammalian cells is enhanced by adenovirus.

E. Green, M. Ashlock, S. Compton, 1997, Nucleic acids research.

Design of modified oligodeoxyribonucleotide probes to detect telomere repeat sequences in FISH assays.

F. Collins, J. Hacia, M. Ashlock, 1999, Nucleic acids research.

Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo

J. Clancy, F. Accurso, M. Ashlock, 2010 .

Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D-CFTR Mutation Treated With VX-770, An Investigational Oral Potentiator Of CFTR

J. Clancy, F. Accurso, M. Ashlock, 2010, ATS 2010.

Final results of a 14- and 28-day study of VX-770 in subjects with CF

J. Clancy, S. Freedman, F. Accurso, 2009 .

Improvement in ion transport biomarkers and spirometry with the investigational CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation

J. Clancy, F. Accurso, J. Pilewski, 2010 .

Rescue of the protein folding defect in cystic fibrosis in vitro by the investigational small molecule, VX-809

P. Negulescu, P. Grootenhuis, J. Wine, 2010 .

Personalized medicine for cystic fibrosis: the next generation.

M. Ashlock, 2011 .

"If a genotype-directed cystic fibrosis transmembrane conductance regulator modulator is approved for use in cystic fibrosis, unprecedented opportunities will occur and new challenges may emerge."

M. Ashlock, 2011 .

An improved method for routine preparation of intact artificial chromosome DNA (340-1000 kb) for transfection into human cells.

M. Ashlock, K. Henning, S. Compton, 1999, Nucleic Acids Research.

cis-Acting elements within CFTR 5'-flanking DNA are not sufficient to decrease gene expression in response to phorbol ester.

M. Ashlock, P. Zeitlin, P. Mogayzel, 2002, Biochimica et biophysica acta.

Introduction to Section I: the relevance of CF diagnostic tools for measuring restoration of CFTR function after therapeutic interventions in human clinical trials.

M. Ashlock, K. De Boeck, 2011, Methods in molecular biology.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

F. Accurso, M. Ashlock, M. Konstan, 2012 .

A pipeline of therapies for cystic fibrosis.

C. Penland, M. Ashlock, B. Ramsey, 2009, Seminars in respiratory and critical care medicine.